Generated: December 15, 2017
DrugPatentWatch Database Preview
Details for Patent: 4,866,048
« Back to Dashboard
Summary for Patent: 4,866,048
|Title:|| Novel vitamin D analogues|
|Abstract:||This invention relates to vitamin D analogues represented by the general formula I ##STR1## in which formula X stands for hydrogen, lower alkyl, halogen or hydroxy; Y stands for hydrogen or hydroxy; R.sup.1 and R.sup.2, which may be the same or different, stand for lower alkyl, optionally substituted with halogen or hydroxy with the proviso that R.sup.1 and R.sup.2 cannot both be methyl when X is other than lower alkyl, or, taken together with the carbon atom numbered 25, R.sup.1 and R.sup.2 can form a saturated or unsaturated C.sub.3 -C.sub.9 carbocyclic ring which may optionally be substituted at any possible position(s) with lower alkyl, halogen or hydroxy; R.sup.3 stands for hydrogen or lower alkyl; R.sup.4 and R.sup.5 represent either each hydrogen, or when taken together constitute a bond, with the result that a double bond connects carbon atoms numbered 22 and 23; and bioreversible derivatives thereof. The compounds of the invention have a favorable therapeutic index and are particularly useful in the treatment of human and veterinary disorders which are characterized by abnormal cell proliferation and/or cell differentiation.|
|Inventor(s):|| Calverley; Martin J. (Ballerup, DK), Binderup; Ernst T. (T.ang.strup, DK) |
|Assignee:|| Leo Pharmaceutical Products Ltd. (Ballerup, DK) |
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition; |
No matches for this query
Foreign Priority and PCT Information for Patent: 4,866,048
|Foriegn Application Priority Data|
||Foreign Patent Number
||Foreign Patent Date
|United Kingdom||8519502||Aug 02, 1985|
|PCT Filed||July 14, 1986||PCT Application Number:||PCT/DK86/00081|
|PCT Publication Date:||February 12, 1987||PCT Publication Number:||
International Patent Family for Patent: 4,866,048
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.